Esperion Therapeutics Inc., (Nasdaq: ESPR), the pharmaceutical company developing promising new cholesterol therapies, reported a big loss for 2013 — but continued promising clincal trial results.
Rofin-Sinar Technologies Inc., a Plymouth maker of industrial lasers, announced that it had an agreement to acquire the assets of Portland, Ore.-based FiLaser USA LLC.
The weight of this season’s snow may be to blame for a roof collapse in Plymouth.
Both Midland-based Dow Corning Corp. and Rofin-Sinar Technologies Inc. of Plymouth reported earnings this week for the quarter ended Dec. 31.
The cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
Esperion Therapeutics Inc. (Nasdaq: ESPR) says its shares have been added to the Nasdaq Biotechnology Index effetive Dec. 23.
Plymouth-based Humanetics Innovative Solutions Inc. and affiliated companies Wednesday announced their acquisition by Golden Gate Capital, a San Francisco private equity firm.
The pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today’s cholesterol-lowering statin drugs.
In the devastating aftermath of Typhoon Haiyan, Comcast Corp. Wednesay announced that it is offering free calls to the Philippines to its 10.5 million Xfinity Voice residential customers.
The industrial laser maker Rofin-Sinar Technologies Inc. (Nasdaq: RSTI), based in Plymouth and in Hamburg, Germany, Thursday reported net income of $9.8 million for its fourth fiscal quarter ended Sept. 30, down 3 percent from $10.1 million in the same quarter a year earlier.